Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma

被引：6

作者：

Xu, Lin ^{[1
]}

Wang, Boqing ^{[1
]}

Ding, Wei ^{[1
]}

机构：

[1] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Hepatopancreatobiliary Surg, Urumqi 830000, Peoples R China

来源：

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY | 2017年 / 41卷 / 02期

关键词：

D O I：

10.1016/j.clinre.2016.12.005

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：E24 / E25

页数：2

共 5 条

[1]

Aragon-Ching JB, ACTA ONCOL

[2] Targeted therapy for hepatocellular carcinoma: novel agents on the horizon [J].

Cervello, Melchiorre ;

McCubrey, James A. ;

Cusimano, Antonella ;

Lampiasi, Nadia ;

Azzolina, Antonina ;

Montalto, Giuseppe .

ONCOTARGET, 2012, 3 (03) :236-260

[3] Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome [J].

Neptune, ER ;

Frischmeyer, PA ;

Arking, DE ;

Myers, L ;

Bunton, TE ;

Gayraud, B ;

Ramirez, F ;

Sakai, LY ;

Dietz, HC .

NATURE GENETICS, 2003, 33 (03) :407-411

[4]

Suarez C, 2010, ANN ONCOL, V21

[5] Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis [J].

Wu, Shenhong ;

Chen, John J. ;

Kudelka, Andrzej ;

Lu, Janice ;

Zhu, Xiaolei .

LANCET ONCOLOGY, 2008, 9 (02) :117-123

← 1 →